The heterogeneity of ovarian cancer

Archives of Gynecology and Obstetrics

Volumn 289, Issue 2, 2014, Pages 237-239

  Meinhold Heerlein, I ^a,b   Hauptmann, S ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Institute of Pathology   (Germany)

Author keywords

Borderline tumors of the ovary; Heterogeneity; Ovarian cancer; Pathogenesis

Indexed keywords

CANCER GRADING; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HOX GENE; HUMAN; MOLECULAR PATHOLOGY; OVARY CANCER; REVIEW; TUMOR SUPPRESSOR GENE; UTERINE TUBE; CELL TRANSFORMATION; DISEASE COURSE; FALLOPIAN TUBE NEOPLASMS; GENETICS; MOLECULAR BIOLOGY; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; PROGNOSIS; RISK FACTOR; SURVIVAL; TUMOR INVASION;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MOLECULAR BIOLOGY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84899102688     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-3114-3     Document Type: Review

References (13)

1. Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5):1511-1518
2. Du Bois A, Ewald-Riegler N et al (2009) Borderline-Tumoren des Ovars-eine systematische übersicht. Geburtsh Frauenheilk 69:807-833
3. Seidman JD, Kurman RJ (2000) Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31(5):539-557
4. Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433-443
5. Kurman RJ, Shih Ie M (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27(2):151-160
6. Heintz AP, Odicino F et al (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):161-192
7. Meinhold-Heerlein I, Bauerschlag D et al (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24(6):1053-1065
8. Fleming JS, Beaugie CR et al (2006) Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 247(1-2):4-21
9. Jazaeri AA (2009) Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Mol Oncol 3(2):151-156
10. Bauerschlag DO, Schem C et al (2009) The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. J Cancer Res Clin Oncol 136(1):79-88
11. Hauptmann S, Denkert C et al (2002) Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 33(6):632-641
12. Shih Ie M, Kurman RJ (2005) Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11(20):7273-7279
13. Hennessy BT, Coleman RL et al (2009) Ovarian cancer. Lancet 374(9698):1371-1382